BANK VONTOBEL/CALL/ELI LILLY & CO/820/0.1/20.09.24 | Delayed Deutsche Boerse AG 11:05:45 2024-06-21 am EDT | ||
| 9.29 EUR | +3.68% |
|
| Current month | +67.16% | ||
| 1 month | +128.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 9.29 | +3.68% |
| 24-06-20 | 8.96 | -8.76% |
| 24-06-19 | 9.82 | +7.32% |
| 24-06-18 | 9.15 | -4.19% |
| 24-06-17 | 9.55 | +8.52% |
Delayed Quote Deutsche Boerse AG
Last update June 21, 2024 at 11:05 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VM9ZDV |
| ISIN | DE000VM9ZDV6 |
| Date issued | 2024-02-07 |
| Strike | 820 $ |
| Maturity | 2024-09-20 (91 Days) |
| Parity | 10 : 1 |
| Emission price | 2.79 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.14 € |
|---|---|
| Lowest since issue | 2.47 € |
| Spread | 0.02 € |
| Spread % | 0.22% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
886
USD
Average target price
855.4
USD
Spread / Average Target
-3.45%
- Stock Market
- Warrants
- Warrant
